The Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) operated
by Leidos Biomedical Research, Inc., (formerly SAIC-Frederick, Inc.) for the National Cancer Institute
(NCI), part of the U.S. National Institutes of Health (NIH). FNLCR is a government-owned, contractor-operated
facility, one of the nation's 39 FFRDC's
and the only one devoted exclusively to biomedical research and development.
Frederick National Lab provides quick response capabilities and meets special long-term research and
development needs for NCI that cannot be met as effectively by existing in-house or contractor resources.
The FFRDC also supports other institutes of NIH and wide range of research collaborations and
partnerships with third parties, consistent with NCI's mission.
The Frederick National Laboratory conducts basic, translational, and preclinical
research and development in cancer and AIDS. FNLCR investigators and technical staff collaborate with
other government agencies, academic institutions, life-science companies, and nonprofit research organizations to develop
the next generation of tests and treatments that will benefit families affected by cancer.
The lab has established a program through which
outside organizations -- including life science companies and other commercial entities -- can
enter directly into cooperative research and development agreements with Leidos Biomedical
Research. These agreements can accommodate the development of new technologies for research,
or for clinical applications that benefit patients. Under the agreements, partners can have
first option to exclusive or nonexclusive commercial license.
The Frederick National Lab offers education, training, and
professional development, as well as expert consultation
in quality control, regulatory affairs, and patient safety. As a national resource, FNLCR helps biomedical
scientists form a solid bridge between basic research and clinical practice, with support that is not readily
Typed the characters seen in the image below to continue.
Sending Mail ...